Your browser is no longer supported. Please, upgrade your browser.
Rallybio Corporation
Index- P/E- EPS (ttm)-5.11 Insider Own3.90% Shs Outstand27.53M Perf Week1.75%
Market Cap335.77M Forward P/E- EPS next Y-2.79 Insider Trans2.43% Shs Float8.00M Perf Month6.34%
Income- PEG- EPS next Q-0.41 Inst Own75.10% Short Float5.98% Perf Quarter-41.55%
Sales- P/S- EPS this Y2.90% Inst Trans0.17% Short Ratio10.16 Perf Half Y-29.86%
Book/sh6.77 P/B1.46 EPS next Y3.50% ROA- Target Price30.00 Perf Year-
Cash/sh5.51 P/C1.80 EPS next 5Y- ROE- 52W Range8.06 - 25.78 Perf YTD3.67%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-60.94% Beta-
Dividend %- Quick Ratio26.20 Sales past 5Y- Gross Margin- 52W Low24.94% ATR1.23
Employees31 Current Ratio26.20 Sales Q/Q- Oper. Margin- RSI (14)51.04 Volatility14.20% 13.86%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.06 Prev Close9.89
ShortableYes LT Debt/Eq0.00 EarningsNov 10 BMO Payout- Avg Volume47.09K Price10.07
Recom1.70 SMA206.52% SMA50-6.87% SMA200-27.35% Volume815 Change1.82%
Aug-23-21Initiated Jefferies Buy $20
Aug-23-21Initiated Evercore ISI Outperform $40
Aug-23-21Initiated Cowen Outperform
Jan-27-22 08:49AM  
Jan-18-22 08:00AM  
Jan-06-22 08:00AM  
Dec-30-21 05:33AM  
Dec-08-21 07:38PM  
Dec-01-21 07:26AM  
Nov-24-21 08:00AM  
Nov-11-21 08:00AM  
Nov-10-21 07:00AM  
Oct-29-21 10:49AM  
Sep-09-21 07:00AM  
Aug-02-21 04:05PM  
Jul-28-21 09:10PM  
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fryer Jeffrey MSee RemarksJan 19Buy8.701,40012,18044,048Jan 21 06:22 PM
Uden StephenSee RemarksJan 13Buy9.155,00045,752719,127Jan 14 08:11 PM
Uden StephenSee RemarksJan 12Buy10.555,00052,750714,127Jan 14 08:11 PM
MACKAY MARTINChief Executive OfficerJan 11Buy10.654,49647,882282,609Jan 12 06:56 PM
MACKAY MARTINChief Executive OfficerJan 10Buy10.105,50455,590278,113Jan 12 06:56 PM
Fryer Jeffrey MSee RemarksJan 07Buy9.4110,00094,06942,648Jan 11 08:03 PM